Please use a minimum of three unique search words
Our search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Emgality ® ▼ (galcanezumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information.For current prescribing information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
How should Emgality®▼ (galcanezumab) be stored during transport and travel?
Keep as cool as possible when travelling, ideally store galcanezumab at 2°C to 8°C. Protect the medicine from light and do not freeze. Please find below storage information depending on type of travel.
Transporting the device from the pharmacy
Galcanezumab may be transported from the pharmacy outside refrigeration up to a maximum of 4 hours unharmed. Protect the device from light. Do not expose the device to freezing conditions (at or below 0 °C ) or temperatures above 30 °C.1
Travelling with the device
Keep the medicine as cool as possible while travelling.
- Store the medicine at 2°C to 8°C to best protect the medicine.
- Do not freeze.
- Store galcanezumab in the original package to protect from light.2
Galcanezumab may be stored unrefrigerated for single period up to 7 days at temperatures up to 30 °C. If the device is stored at a higher temperature or for a longer period it must be discarded.2
If galcanezumab has been intentionally stored at room temperature, it should not be returned to the refrigerator. Discard, if not used within 7 days.1
While travelling we recommend the patient carries the medicine with them at all times (e.g. plane, car, bus, train, etc.).1
The medicines should never be packed in with checked luggage. It is possible for luggage hold areas to have wide changes in temperatures. These temperatures may become too cold or too hot and this will affect the medicine.1
Travel cooler bags
Eli Lilly and Company (Lilly) does not provide cooler bags to travel with the device. Please refer to a pharmacist to discuss available equipment suitable to keep the medicine cool while traveling. Lilly does not test, market or sell these products, therefore, we cannot make recommendations.1
If the patient uses a cooler, it is important they keep the device away from direct contact with ice, frozen gel packs or freezing temperatures (0°C or below). The medicine should always be protected from light and freezing temperatures.1
Impact of altitude
Changes in altitude that may be experienced when travelling do not impact the dose accuracy of the device.1
Airport screening/x-ray impact
The screening equipment used at airports (X-rays) are not known to affect the medicine. If preferred, the medicines and supplies can be inspected by hand when the patient goes through security checkpoints, on request.1
Before travelling the patient should check with the airline company to find out what the current travel policies are for travelling with medicine on board the plane. If travelling internationally, the patient should also check with the authorities in the country they plan to visit.1
1Data on file, Eli Lilly and Company and/or one of its subsidiaries.
2Emgality [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Date of Last Review: 05 January 2022